Activation of systemic antitumor immunity via TRAIL-induced apoptosis

TNF-related apoptosis-inducing ligand (TRAIL) continues to be intently studied as a cancer therapeutic because of its selective tumoricial activity. We have been interesting in evaluating the ability of TRAIL to induce systemic antitumor immunity through the generation of apoptotic tumor cells. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Britnie R., Griffith, Thomas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494637/
https://www.ncbi.nlm.nih.gov/pubmed/23170271
http://dx.doi.org/10.4161/onci.20638
Descripción
Sumario:TNF-related apoptosis-inducing ligand (TRAIL) continues to be intently studied as a cancer therapeutic because of its selective tumoricial activity. We have been interesting in evaluating the ability of TRAIL to induce systemic antitumor immunity through the generation of apoptotic tumor cells. Recent observations suggest that localized administration of TRAIL in combination with CpG ODN generates a systemic antitumor immune response to eliminate the primary tumor and distant metastases.

Ejemplares similares